Teva Raises Guidance As Generics Enjoy Solid Growth In Q2

Biosimilars Business Boosted By Adalimumab Launch In US Ahead Of Ustekinumab Opportunity

 
• By David Wallace
  
Teva logo outside building
Teva reported double-digit growth for generics in the second quarter • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business